GEN Exclusives

More »

GEN News Highlights

More »
Mar 6, 2007

Shionogi Pays $14M for BioCryst’s Influenza Program in Japan

  • BioCryst Pharmaceuticals and Shionogi & Co. entered into an exclusive license agreement to develop and commercialize BioCryst's lead influenza neuraminidase inhibitor, peramivir, in Japan for the treatment of seasonal and potentially life-threatening human influenza.

    Shionogi will pay $14 million for rights to injectable formulations of peramivir. BioCryst may also receive future clinical  event payments of up to $21 million, commercial milestones of up to $95 million, and double digit royalty payments, ranging between 10% and 20%.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?